Considering that IL-17 antagonist molecules have recently emerged as therapeutics, this finding may suggest a basis to explore their therapeutic potential in T2DM affected peri-implantitis patients (Abdel-Moneim, Bakery & Allam, 2018). This evidence concerns the gene IL17A and type 2 diabetes mellitus.